With use of a novel model of invasive Aspergillus fumigatus, the efficacy of prophylactic versus therapeutic administration of liposomal amphotericin B (L-AmB) was tested in C57BL/6 mice. After lethal irradiation and transplantation of whole bone marrow (d 0), animals were challenged with conidia either intravenously or via nasal instillation on d +3 and divided into 3 groups: group I received 5% dextrose in water throughout the study period; group II received L-AmB, 5 mg/kg, beginning on d +4; and group III received L-AmB, 5 mg/ kg on d Ϫ4, d Ϫ2, d 0, and d +2, then daily starting d +4. Groups I and II did not survive intravenous challenge, whereas group III had a 40% survival rate. After nasal instillation of conidia, the survival was 25%, 35%, and 85% for mice in groups I, II, and III, respectively. These results demonstrate that prophylactic administration of L-AmB increased early survival against lethal challenge with A. fumigatus, compared with therapy instituted after infection.
Since the advent of prophylactic, preemptive, and treatment strategies for the treatment of cytomegalovirus, invasive aspergillosis has emerged as the most lethal infectious complication after allogeneic hematopoietic cell transplantation (HCT). Modifications in the chemotherapeutic preparative regimens and the transplanted grafts have resulted in a significant shortening of the period of neutropenia. However, the incidence of invasive aspergillosis remains between 8% and 15%. Furthermore, mortality after diagnosis of either proved or probable invasive aspergillosis in the setting of allogeneic HCT is 92%-100%, despite aggressive treatment with a growing roster of appropriate antifungal agents [1] . Therefore, the lethality of this infection underscores the necessity of preventing this infection.
Empiric institution of broad-spectrum antifungal therapy for fever unresponsive to 3-4 days of antibacterial administration is a widely accepted practice, but the nephrotoxicity of amphotericin B deoxycholate (D-AmB) precludes full-dose therapy in patients who have undergone HCT. The reduced potential for nephrotoxicity of the lipid formulations of amphotericin B (L-AmB) permits administration of higher doses even after HCT, and L-AmB has been shown to have the least potential for nephrotoxicity [2] . These lipid formulations reach significant concentrations in the lung, liver, spleen, brain, and kidneys, especially after administration of higher doses. However, in a recent multicenter trial [3] , empiric administration of either DAmB or L-AmB still resulted in a significant number of proved or probable breakthrough fungal infections during the brief 7-day follow-up period, of which the most common breakthrough pathogen was Aspergillus fumigatus.
As a result of such breakthrough infections, a limited number of prophylactic strategies have been tested clinically. Fluconazole has been shown to reduce the incidence and mortality caused by systemic Candida albicans infections after HCT, but, as would be predicted, the incidence of mold infections was unchanged. Although prophylactic administration of oral itraconazole solution has been reported to reduce death caused by proven fungal infections, these studies included only a limited number of HCT recipients, and breakthrough aspergillus infections still occurred [4] .
The protracted postdosing and broad-spectrum antifungal activity of L-AmB suggests a favorable profile for its use in a prophylactic strategy [5] . In the 2 published studies of prophylactic administration of 1-2 mg/kg of L-AmB after HCT, fungal colonization was reduced, but decreases in reported mortality could not be attributed to a decrease in fungal-related deaths [6, 7] . These equivocal results may be explained by pharmacokinetic studies in animals that demonstrate the need for doses 11-2 mg/kg to achieve significant tissue levels in all organs. On the basis of these findings, a single high dose of L-AmB given up to 1 week prior to challenge was shown to reduce the growth of C. albicans and Histoplasma capsulatum in mice during chemotherapy-induced neutropenia [8] .
Demonstrating the efficacy of antifungal agents with activity against aspergillus has been more problematic. Published murine models of invasive aspergillosis have relied on chemotherapy-induced neutropenia or corticosteroids to render the mice susceptible to infection. No prophylactic studies have been published that have used animal models that replicate the immunodeficiency that results from HCT. Therefore, a murine model was developed to study the efficacy of prophylactic versus early treatment in the face of lethal challenge. The results of the present study demonstrate that prophylactic administration of L-AmB was more effective in preventing death than administration of L-AmB started within 24 h after fungal challenge.
Materials and Methods
Mouse strains. Congenic strains of C57BL/6 mice were used as donors and recipients. Donor mice were used at age 6-8 weeks and recipients at age 12-16 weeks.
Irradiation. Host mice received a total dose of 950 cGy administered at 3-h intervals (200-kV machine; Philips RT250) and were provided with water that contained 1.1 g/L neomycin sulfate and 10 6 U/L polymyxin B sulfate for the duration of the study. Isolation of whole bone marrow. Whole bone marrow cells were harvested by use of Hanks' balanced salt solution with 2% fetal calf serum, penicillin, and streptomycin (Gibco BRL). Erythrocytes were depleted via ammonium-chloride lysis, washed twice with media to remove residual lysing solution, and kept on ice until transplantation.
Transplantation of whole bone marrow cells. Mice were anesthetized in a chamber saturated with a mixture of Isoflurane (Abbott Laboratories) and oxygen. One million whole bone marrow cells were transplanted into the retro-orbital vein.
Administration of L-AmB. L-AmB (AmBisome; Fujisawa Healthcare) was reconstituted according to the manufacturer's specifications. Appropriate dilutions were made with use of sterile 5% dextrose in water (D 5 W) for injection via the tail vein each day. Mice were matched for age, sex, and weight for each experiment and divided into groups that received the following: group I, intravenous (iv) administration of D 5 Preparation of Aspergillus conidia. An isolate of A. fumigatus known to cause fatal sinusitis in a patient after allogeneic HCT was plated onto Sabouraud dextrose agar (SDA; Becton Dickinson) and incubated for 48 h at 37ЊC. Sterile saline was poured onto the surface of the fungal lawn, which was scraped gently with an inoculating loop. Conidia were resuspended in normal saline and filtered through sterile gauze. The suspension was examined for hyphal elements, and the concentration of conidia was determined by both counts and colony growth. Suspensions were stored at 4ЊC. Culture of target organs. Mice were killed if they exhibited clinical evidence of disease or 20% loss of baseline body weight; all remaining surviving mice were killed at the end of the 24-day study period. Spleen, liver, kidneys, lungs, and brains were harvested, weighed, and then homogenized with 2 mL of Dulbecco's modified Eagle medium (Gibco BRL). Tissue homogenate (0.3 mL) was plated on freshly made SDA plates and incubated at room temperature. Colonies were counted at 5, 7, and 10 days after plating. Fragments of organs were also fixed for histologic examination.
Statistics. The log-rank test was used for paired data analyses of the Kaplan-Meier survival curves.
Results
After transplantation, mice remained neutropenic for a minimum of 14 days. A control group of mice that received D 5 W daily after transplantation but were not infected remained healthy throughout the study period. Mice that served as controls for the lethal irradiation dose died between d ϩ12 and d ϩ14.
iv Challenge with A. fumigatus. After iv challenge with conidia, all mice that received only D 5 W (group I) throughout the study period or that received L-AmB only after challenge (group II) died within 1 week. In contrast, 40% of the mice in group III survived ( ) for 24 days after transplantation P ! .05 and were killed for culture and histologic examination of their organs ( figure 1A) .
Intranasal (inl) challenge with A. fumigatus. After nasal instillation of conidia, only 25% and 35% of the mice in groups I and II, respectively, survived. In contrast, 85% of mice that received L-AmB prior to and after challenge (group III; P ! ) survived for the remainder of the 24-day study period. The .05 administration of 1 mg/kg/d of L-AmB (group IV) prior to challenge did not result in a significantly improved survival, compared with group I ( figure 1B) .
Tissue fungus load. Four days after inl administration of conidia, a high fungus load in the lungs of moribund mice in groups I, II, and IV was confirmed by culture. Acutely branching hyphae elements consistent with A. fumigatus could be readily seen in histologic samples of the lung. Of interest, fungal tissue load remained significant even in the surviving mice in group II. In contrast, no fungus was isolated from the tissue of mice that had received prophylactic administration of LAmB. Mice in group III did not display evidence of illness throughout the study period (table 1). After iv challenge, A. fumigatus could not be isolated from the tissue of any of the surviving mice (group III) on d ϩ24.
Discussion
Invasive aspergillosis after HCT has an inordinately high fatality rate, despite early administration of appropriate antifungal agents. Clinical studies have invariably confirmed the occurrence of breakthrough mold infections after administration of even broad-spectrum antifungal agents when they are administered empirically [2, 9, 10] . In a well-designed clinical trial that compared empiric D-AmB therapy with L-AmB therapy, the total incidence of proved and probable fungal infections did not appear to be significantly different between the groups [3] . Thus, until there are significant improvements in the immunosuppressive regimens used after transplantation or proven immunotherapy, the prevention of aspergillosis remains the most effective strategy in decreasing death due to this infection.
The pharmacokinetic and toxicity profile of L-AmB is more favorable than that of D-AmB, making full-dose therapy possible even after HCT and a reasonable choice for a prophylactic drug. L-AmB has also been shown to reduce dissemination of infection compared with D-AmB in a rat model of pulmonary aspergillosis [11] and to prevent murine systemic candidiasis and histoplasmosis [8] . However, prophylactic administration of low doses of L-AmB [6, 7] has been shown to significantly decrease only fungal colonization, not the incidence of invasive fungal infections or mortality in neutropenic patients or after HCT.
Other animal models of invasive aspergillosis have relied on chemotherapy-induced neutropenia with or without corticosteroids to render the mice susceptible to infection. In those models, the number of conidia required to induce lethal disease has been reported to be between and with iv injec- 5 8 1 ϫ 10 1 ϫ 10 tion and between and with inl administration 4 6 1 ϫ 10 1 ϫ 10 [12] . In our model of lethal irradiation and HCT, although both the lethal iv and inl doses are decreased, there was a less dramatic impact on the lethal inl dose, which suggests that the alveolar macrophage population is not as radiosensitive as the hematopoietic populations. The profound immunopathology demonstrated by this preclinical model parallels the increased mortality in patients after HCT, compared with patients who have other risk factors for invasive aspergillosis.
The data presented show that prophylactic administration of L-AmB is superior to treatment started even very early postinfection after HCT in the protection against lethal invasive aspergillosis. In addition, prophylactic administration of L-AmB resulted in greater protection against death after inl administration of conidia compared with iv inoculation. This may be due to differences in effective drug concentrations relative to the delivery of the conidia or differences in the degree of compromise of the local immune effect cells. The trend toward an increased latency to death in the mice that received prophylactic administration of L-AmB may also suggest that the presence of drug in tissues at the time of infection may slow fungal proliferation. The absence of a protective effect of 1 mg/kg/d of L-AmB is also consistent with limited clinical studies. The ability to isolate fungus from the lungs of the survivors that received L-AmB daily beginning 36 h after infection suggests that, once established, it is difficult to eradicate the fungus, which further underscores the need for prevention.
The prevention of death due to invasive aspergillosis in this preclinical model of HCT suggests that the results in clinical trials of antifungal prophylaxis with L-AmB were equivocal because of an inadequate dose of L-AmB. Because tissue accumulation of L-AmB follows nonlinear and progressive pharmacokinetics (clearance and volume decreased and half-life increased with dose and time), 5 mg/kg has been shown to result in disproportionately higher tissue levels in the liver, spleen, lung, kidneys, and plasma than 1-2 mg/kg [5, [13] [14] [15] .
The laboratory and clinical studies cited have demonstrated that chemoprophylaxis of invasive candidal infections is possible. The results reported herein are the first demonstration that invasive aspergillosis also can be prevented even in the setting of severe immune compromise.
